FOLH1 and prostate cancer: Some examples include Lutathera (lutetium 177Lu dotatate), the first FDA and EMA approved theranostic drug, which releases radiation to kill cancer cells by binding to cell surface receptors somatostatin on gastroenteropancreatic neuroendocrine tumors (116), and Pluvicto for castration-resistance prostate cancer using Lutetium-177 that targets PSMA on cell surface in prostate cancer (117).